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http://dx.doi.org/10.1016/j.ccr.2013.10.009SUMMARYA large body of evidence indicates that chronic inflammation is one of several key risk factors for cancer
initiation, progression, and metastasis. However, the underlying mechanisms responsible for the contribu-
tion of inflammation and inflammatorymediators to cancer remain elusive. Here, we present genetic evidence
that loss of CXCR2 dramatically suppresses chronic colonic inflammation and colitis-associated tumorigen-
esis through inhibiting infiltration of myeloid-derived suppressor cells (MDSCs) into colonic mucosa and
tumors in a mouse model of colitis-associated cancer. CXCR2 ligands were elevated in inflamed colonic
mucosa and tumors and induced MDSC chemotaxis. Adoptive transfer of wild-type MDSCs into Cxcr2/
mice restored AOM/DSS-induced tumor progression. MDSCs accelerated tumor growth by inhibiting
CD8+ T cell cytotoxic activity.INTRODUCTION
Colorectal cancer (CRC) is the fourth most common malignant
neoplasm and the second leading cause of cancer deaths in
the United States. Although colonoscopy screening is an effec-
tive way to detect and prevent CRC by removing precancerous
adenomas (Zauber et al., 2012), 70% of patients with CRC pre-
sent to their physician with advanced disease, resulting in an
unacceptable 5 year survival rate (Yamashita and Watanabe,
2009). CRC includes hereditary, sporadic, and colitis-associated
CRC. In addition to somatic mutations and epigenetic changes,
epidemiologic and experimental evidence strongly implicates
chronic inflammatory stimuli as a risk factor for developing
CRC. Indeed, ulcerative colitis (UC), a form of inflammatory
bowel disease (IBD), is associated with an increased risk for
the development of CRC (Ekbom et al., 1990). More than 20%
of patients with UC are reported to develop colitis-associatedSignificance
Until now, CXCR2was only thought tomediate infiltration of ne
is also required for homing of MDSCs into colonic mucosa and
recruitment of MDSCs from the circulatory system to local tissu
adoptive transfer of MDSCs provide direct evidence that M
Moreover, we also found that colonic MDSCs inhibited CD8+
a rationale for the development of therapeutic approaches to
suppression by using CXCR2 antagonists and neutralizing ant
CanCRC within 30 years of diagnosis (Lakatos and Lakatos, 2008).
Colitis-associated cancer often shows rapid progression, with
poor response to treatment and high mortality (Feagins et al.,
2009). Since there is a strong association between chronic
inflammation and CRC in IBD patients, studies on colitis-associ-
ated CRC provides a ‘‘proof of concept’’ model to better
understand how chronic inflammation and certain inflammatory
mediators promote tumor initiation, growth, and metastasis.
Chronic inflammation is caused by a persistently heightened
immune response following injury or exposure to foreign patho-
gens. For example, disruption of immune homeostasis in the
intestine in response to the gut flora, which contains foreign
luminal antigens from food and commensal bacteria, can result
in the development of IBD. The importance of flora for IBD is
evident by the observations that antibiotic treatment and/or
probiotic therapy have been shown to be benefits for, at least,
subsets of IBD patients (Gionchetti et al., 2003; Sutherlandutrophils to inflammatory sites. Our results show that CXCR2
colitis-associated tumors, revealing a role of CXCR2 in the
es and tumors. Importantly, our results from experiments of
DSCs contribute to colonic tumor formation and growth.
T cell cytotoxicity against tumor cells. Our findings provide
subvert chronic inflammation- and tumor-induced immuno-
ibodies.
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Figure 1. Deletion of Cxcr2 Attenuates AOM/DSS-Induced Colonic Chronic Inflammation and Colitis-Associated Tumor Formation, Growth,
and Progression
(A) Schematic of mice treated with AOM and DSS (A/D).
(B) The colon lengths were measured following treatment.
(C) Representative of hematoxylin and eosin (H&E)-stained sections from WT (top) and Cxcr2 null mice (bottom). Scale bar, 100 mm.
(D) Blinded histological scoring of inflammation in colonic mucosa of mice was performed as described in the Experimental Procedures.
(E) Tumor number and size were measured under a dissecting microscope.
(legend continued on next page)
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CXCR2 and MDSC in Colitis-Associated Tumorigenesiset al., 1991). Direct evidence for the role of luminal flora came
from animal studies showing that chronic colitis is dependent
on their presence (Elson et al., 2005). Antibiotic treatment and/
or probiotic therapy attenuated colon chronic inflammation in
different mouse models of IBD, including dextran sulfate sodium
(DSS)-treated mice (Garrido-Mesa et al., 2011a, 2011b). In a
mouse model of colitis-associated cancer, germ-free azoxyme-
thane (AOM)-treated Il10/ mice exhibited normal colon histol-
ogy and did not develop colon tumors (Uronis et al., 2009). Even
in a mouse model of hereditary and sporadic CRC, antibiotic
treatment reduced tumor burden, indicating that the luminal
bacteria contributes to tumor growth (Grivennikov et al., 2012).
Of note, several in vivo studies showed that pathogenic bacteria
from gut flora induced expression of the inflammatory enzyme
cyclooxygenase 2 (COX-2) in inflamed colonic mucosa (Abdallah
Hajj Hussein et al., 2012; Cho and Chae, 2004; Lee and Kim,
2011). The levels of COX-2 and COX-2-derived prostaglandin
E2 (PGE2) are known to be markedly elevated in the gastrointes-
tinal tracts of patients with IBD (Lauritsen et al., 1986; Singer
et al., 1998).
The main pathological feature of IBD involves a massive
infiltration of neutrophils, lymphocytes, and monocytes into
the inflamed intestinal tissue. Similarly, the common patholog-
ical changes associated with colitis-associated and sporadic
CRC include recruitment and reprogramming of various types
of dysregulated immune cells and endothelial cells to establish
a tumor microenvironment (Coussens and Werb, 2002; Strober
et al., 2007). Chemokines that recruit leukocytes from the circu-
latory system to local sites of inflammation have emerged as
essential immune molecules in the pathogenesis of IBD and
CRC. Chemokines exert their biological functions via binding
to their cognate G protein-coupled receptors. Elevation of
pro-inflammatory chemokines and a massive infiltration of
leukocytes are all observed in the intestinal mucosa of IBD
patients and strongly correlate with the grade of disease activity
(Fegn and Wang, 2009). Moreover, the levels of these pro-
inflammatory chemokines are also higher in human sporadic
colorectal carcinomas than in matched normal tissues (Fegn
and Wang, 2009). However, it remains unclear how these
chemokines and their receptors contribute to IBD and colitis-
associated carcinogenesis.
Cancer initiation and progression also depends on escape
from host immunosurveillance. Similar to other solid tumors,
CRC immune evasion involves a shift of immune responses,
including imbalance in Th1/Th2 responses and enhancement
of immunosuppressive cells such as myeloid-derived sup-
pressor cells (MDSCs) and regulatory T cells. The number of
MDSCs in the blood correlates well with clinical cancer stage
and metastatic tumor burden in patients, including those with
CRC (Diaz-Montero et al., 2009; Mandruzzato et al., 2009). It
is widely accepted that MDSCs contribute to cancer immune
evasion via suppressing functions of T and natural killer (NK)
cells (Gabrilovich and Nagaraj, 2009). However, it remains(F) Left panel represents immunoreactive staining (brown) for Ki67 (scale bar, 50 m
of each slides from 8 mice for each group.
(G) Representative of H&E-stained sections of colonic tissue with tumors from W
(H) Blinded histological scoring of average percentage of adenocarcinomas in to
Data are represented as mean ± SEM (eight mice for each group). Asterisks rep
Canunclear how MDSCs are recruited from the circulatory system
to the colonic mucosa during chronic inflammation and
carcinogenesis and precisely how local MDSCs contribute to
CRC progression.
Our previous work showed that PGE2 directly stimulated CRC
cells to produce and secrete CXCL1, which in turn resulted in
induction of tumor-associated angiogenesis (Wang et al.,
2006b). CXCL1 is one of the ligands that binds to the chemokine
receptor CXCR2, which was originally found to be expressed on
neutrophils and is crucial for the recruitment of neutrophils to
sites of inflammation (Oppenheim et al., 1991). The serum level
of CXCL1 is significantly elevated in patients with IBD (Alzoghaibi
et al., 2008). Importantly, CXCL1 levels also correlate well with
the grade of disease and are reduced after initiation of therapy
(Mitsuyama et al., 2006). Similarly, our group and others showed
that CXCL1 and its receptor CXCR2 are elevated in human
sporadic CRC (Rubie et al., 2008; Wang et al., 2006b; Wen
et al., 2006). However, the mechanisms underlying the contribu-
tion of this signaling pathway to inflammatory disease and CRC
remain elusive.
RESULTS
Deletion of Cxcr2 Attenuates AOM/DSS-Induced
Colonic Chronic Inflammation and Colitis-Associated
Tumorigenesis
To investigate the role of CXCR2 in colitis-associated tumori-
genesis, wild-type (WT) or Cxcr2/ mice were treated with
AOM and DSS as indicated in Figure 1A. AOM/DSS treatment
induced inflammation in the large intestine of WT mice, result-
ing in clear clinical signs such as bloody stools (data not
shown) and shortening of colon length (Figure 1B) but did not
significantly affect mouse body weight (data not shown). In
contrast, deletion of Cxcr2 significantly attenuated the pres-
ence of inflammation-induced bloody stools (p = 0.041) and
shortening of the colon (Figure 1B). Moreover, repeated admin-
istration of DSS induced chronic inflammation in WT mice but
not in Cxcr2/ mice (Figures 1C and 1D). Water-treated WT
and Cxcr2-deficient mice showed no clinical and histologic
signs of chronic colonic inflammation (data not shown). In
addition, loss of Cxcr2 dramatically reduced tumor burden
by inhibition of tumor cell proliferation (Figures 1E and 1F).
The severity of chronic inflammation directly correlated with
tumor multiplicity (data not shown). Histological analysis
revealed that 21% of tumors were adenocarcinomas in AOM/
DSS-treated WT mice, whereas only 4.6% were adenocarci-
nomas in AOM/DSS-treated Cxcr2-deficent mice (Figures 1G
and 1H), suggesting that the presence of CXCR2 accelerates
tumor progression. However, we did not observe submucosal
invasion of tumor cells in our model. These results demon-
strate that CXCR2 is required for promoting chronic inflam-
mation, tumor formation, growth, and progression in the large
intestine.m) and the right panel represents the average numbers of Ki67+ cells in 4 fields
T and Cxcr2 null mice are shown (scale bar, 100 mm).
tal tumors from WT and Cxcr2-deficient mice.
resent statistical differences (*p < 0.05, **p < 0.01).
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Figure 2. Loss of CXCR2 Inhibits DSS-Induced a Massive Infiltration of MDSCs from Circulatory System to Colon
The indicated genotypic mice aged 8 weeks were treated with four cycles of 1.25% DSS and the cells isolated from indicated organs were subjected to flow
cytometry analysis. Viable granulocytes/monocytes or total cells were gated in a FSC/SSC plot.
(A) The subpopulation of G-MDSCs in colonic mucosa was represented as percentage of gated granulocytes/monocytes cells (left) or as the numbers of
G-MDSCs per gram of eachmouse colon tissue (right). Each dot in the right panel represents the numbers of G-MDSCs in colonic mucosa taken from onemouse.
(legend continued on next page)
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CXCR2 and MDSC in Colitis-Associated TumorigenesisLoss of CXCR2 Diminishes DSS- or AOM/DSS-Induced
Massive Infiltration of Granulocytic MDSCs from the
Circulatory System to Colonic Inflamed Mucosa and
Tumors
To examinewhether CXCR2 is involved in immune cell infiltration,
we first analyzed immunocyte profiles in the colonic mucosa of
mice treated with DSS. We used cell surface markers as
described in recent publications (Daley et al., 2008; Gabrilovich
et al., 2012) to define mouse dendritic cells (DCs), macro-
phages, MDSCs, and neutrophils. Deletion of Cxcr2 did not
affect repeated DSS-induced infiltration of dendritic cells
(CD11c+Ly6G-F4/80), T cells (CD3+), NK cells (CD3-CD49b+),
and NKT cells (CD3+CD49b+) into the colonic mucosa
but resulted in a trend toward reduction of infiltration of
macrophages (CD11b+F4/80+CD11cLy6G) and neutrophils
(Ly6G+CD11cF4/80) during the chronic phase (Figure S1A
available online), although alteration of CXCR2 clearly affected
infiltration of neutrophils in the acute phase (Figure S1B). In
contrast, loss of CXCR2 dramatically suppressed a massive
infiltration of CD11b+Ly6GhighCD11c-F4/80 cells into the colon
in both normal (water as control) and chronic inflammatory (DSS
treatment) conditions (Figure 2A). In mice, the immature myeloid
cells, often called MDSCs, are broadly defined as CD11b+Gr-1+
cells that are further divided into two subsets, granulocytic
(CD11b+Ly6Ghigh) and monocytic (CD11b+Ly6C+) MDSCs (Youn
et al., 2008). In most experimental tumor models, granulocytic
MDSCs (G-MDSCs) are more markedly expanded than mono-
cytic MDSCs (Youn et al., 2008). Similarly, over 90% of MDSCs
expressed bothCD11b and Ly6Gmarkers but not Ly6C,whereas
less than 10% of MDSCs expressed both CD11b and Ly6C
but not Ly6G in DSS-treated mice (Figure 2B). Furthermore, we
found that the status of CXCR2 did not affect the G-MDSC
populations in the bone marrow in both normal and chronic
inflammatory conditions (Figure 2C). Importantly, Cxcr2/
mice exhibited more accumulation of the G-MDSCs in the
circulatory system than WT mice under both normal and chronic
inflammatory conditions (Figure 2C), suggesting that Cxcr2-
deficient G-MDSCs have lost their ability to migrate to
local organs undergoing an inflammatory challenge. Almost all
circulatory G-MDSCs expressed CXCR2 on their cell surface,
whereas 40% of bone marrow G-MDSCs expressed CXCR2
(Figure 2D). Surprisingly, circulating monocytic MDSCs did not
express CXCR2 on their cell surface (Figure 2E). As expected,
circulating CD8+ T cells, NKs, NKT cells as well as colonic fibro-
blasts did not express CXCR2 on their cell surface (Figures S1C
and S1D). However, 67% of neutrophils, 9.5% of monocytes,
and 21% of DCs expressed CXCR2 in circulatory system (Fig-
ure S1C). Similarly to the circulatory system, more G-MDSCs
accumulated in spleen of Cxcr2/ mice than WT mice in both
normal and chronic inflammatory conditions (Figure S1E). Since
treatment of DSS did not induce inflammation in liver and lung,
DSS treatment did not affect infiltration of MDSCs into those
organs (Figure S1E).(B) The profiles of G-MDSCs and monocytic MDSCs in colonic mucosa of water
(C) Data represents the percentage of G-MDSC in total viable cells from bone m
(D) Data represents the percentage of CXCR2+ MDSCs in total G-MDSCs from B
(E) The percentage of CXCR2+ G-MDSCs and monocytic MDSCs in total G-MDS
The error bar indicates ± SEM. *p < 0.05, **p < 0.01. See also Figure S1.
CanAs expected, there was no significant difference of immune
cell profiles between mice treated with DSS alone and AOM
plus DSS (Figures S1A and S2A). Similar to DSS-treated mice,
more G-MDSCs accumulated in the circulatory system of
AOM/DSS-treatedCxcr2/ thanWTmice (Figure 3A). However,
viability of circulatingCxcr2-deficent MDSCs was lower thanWT
MDSCs (Figures S2B and S2C). More intriguingly, a higher
G-MDSC accumulation was observed in tumors than matched
inflammatory mucosa in WT mice treated with AOM/DSS (Fig-
ure 3B). In contrast, loss of CXCR2 significantly reduced recruit-
ment of G-MDSCs into both tumors and the matched inflamed
mucosa (Figure 3B). Similar to DSS treatment, deletion of
Cxcr2 also resulted in an accumulation of G-MDSCs in the
spleen in both water- and AOM/DSS-treated mice (Figure S2D).
However, the size and weight of the spleen ofCxcr2/mice was
bigger and heavier than that of WT mice under both normal and
chronic inflammatory conditions (Figure S2E). This could explain
why the spleens of Cxcr2/ mice have a higher percentage of
G-MDSCs than WT mice. Taken together, these results suggest
that CXCR2 is required for homing of G-MDSCs from the circu-
latory system to inflamed colonic mucosa and tumors.
CXCR2 Mediates Ligand-Induced G-MDSC Chemotaxis
Based on our above results showing that treatment of AOM/DSS
induced a massive infiltration of G-MDSCs into inflamed colonic
mucosa and colitis-associated tumors in WT mice, we postu-
lated that the levels of CXCR2 ligands, which are responsible
for recruitment of CXCR2-expressing immune cells, would be
elevated in colonic inflamed mucosa and tumors. Indeed,
treatment of WT mice with AOM/DSS resulted in elevation of
CXCL1, CXCL2, and CXCL5 in colonic tumors and adjacent
inflamed mucosa as compared to the normal mucosa taken
from water-treated mice (Figure 4A). Levels of these ligands
are higher in tumor tissues than in adjacent inflamed mucosa
(Figure 4A), which correlates with density of G-MDSCs in these
tissues (Figure 3B). The results from in situ hybridization experi-
ments revealed that Cxcl1 and Cxcl2 were mainly expressed in
tumor colonic epithelial cells (Figure S3A). We then determined
whether CXCR2 ligands induced MDSC chemotaxis. As shown
in Figure 4B, CXCL1, CXCL2, and CXCL5 all attracted WT
MDSCs isolated from blood of WT mice but not Cxcr2-deficent
MDSCs, demonstrating that CXCR2 is required for ligand-induc-
tion of MDSC chemotaxis. Since myeloid cells are a major
source of interleukin-6 (IL-6) and the IL-6/Stat3 pathway plays
a key role in immunosuppressive function ofMDSCs (Gabrilovich
and Nagaraj, 2009; Grivennikov et al., 2009), we examined IL-6
levels in the colon and blood of AOM/DSS-treated WT and
Cxcr2 null mice. As expected, the pattern of IL-6 levels in colonic
mucosa and tumors as well as in circulatory system (Figure S3B)
is similar to that of MDSC levels in these organs (Figure 3).
p-Stat3 immunostaining was observed in colonic stromal cells
in WTmice treated with AOM/DSS but not inCxcr2/mice (Fig-
ure S3C). These results indicate that infiltrated MDSCs in the- or DSS-treated WT mice as mentioned above.
arrow (BM) and peripheral blood taken from mice.
M and blood in WT mice.
Cs and monocytic MDSCs.
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Figure 3. Loss of CXCR2 Inhibits
AOM/DSS-Induced Massive Infiltration of
G-MDSCs from the Circulatory System to
Colonic Mucosa and Tumors
G-MDSC percentage in bone marrow and
peripheral blood (A) and G-MDSC numbers in
tumors (T) and adjacent mucosa (N) (B) of mice
treated with AOM/DSS were analyzed by Flow
Cytometry as described Figure 1A. Each dot
represents the percentage of G-MDSCs in BM
and peripheral blood collected from one mouse
(left) and the numbers of G-MDSCs in colonic
tumors and matched mucosa taken from one
mouse (right).
The error bar indicates ±SEM. See also Figure S2.
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results demonstrate that CXCL1/2/5-CXCR2 signaling is respon-
sible for recruitment of G-MDSCs into colonic inflammatory
mucosa and tumors.
An Inflammatory Mediator, PGE2, Upregulates CXCR2
Ligands in Colonic Mucosa and Tumors
Although our previous study demonstrated that PGE2 directly
induced CXCL1 expression in human colorectal carcinoma
cell lines and in a xenograft model (Wang et al., 2006b), it was
uncertain whether this inflammatory mediator regulates
CXCR2 ligands in the DSS and AOM/DSS models as well as
ApcMin/+ mice. The ApcMin/+ mouse carries a point mutation at
one allele of the Apc gene and is used as a model for patients
with familial adenomatous polyposis and a pre-malignant model
for human sporadic CRC. As shown in Figure 5, PGE2 signifi-
cantly induced CXCL1 and CXCL2 expression in the colon of
DSS-treated mice (Figure 5A) and in colonic tumors as well as
adjacent mucosa of AOM/DSS-treated mice (Figure 5B) but
failed to induce CXCL5 expression. Similarly, PGE2 enhanced
only CXCL1 and CXCL2 expression in colonic mucosa and tu-
mors (Figure S4A) but all three ligands in small intestinal mucosa
and tumors in ApcMin/+ mice (Figures S4B and S4C). Interest-
ingly, the levels of these ligands were also elevated in intestinal
tumors as compared to matched mucosa regardless of PGE2
treatment (Figures 5B and S4A–S4C). In contrast, treatment of
ApcMin/+ mice with a selective COX-2 inhibitor, celecoxib,
completely suppressed CXCL1 and CXCL2 expression in intes-
tinal mucosa and tumors (Figure S4D). These results demon-
strate that an inflammatory mediator such as PGE2 is able to
induce CXCR2 ligand expression in intestinal mucosa and tu-
mors. High levels of CXCR2 ligands attract CXCR2-expressing
MDSCs into colonic mucosa and tumors.
Adoptive Transfer of WT MDSCs Restores
Tumorigenesis in Cxcr2–/– Mice
To determine whether lack of MDSC infiltration in colonic tissue
directly results in reduction of colitis-associated tumor burden
in Cxcr2/ mice, adoptive transfer experiments were per-
formed. To first examine whether the adoptive transfer of
G-MDSCs works, G-MDSCs isolated from WT mice were
labeled with a fluorescent dye, XenoLight DiR, and then636 Cancer Cell 24, 631–644, November 11, 2013 ª2013 Elsevier Incinjected into Cxcr2 null mice. After 2 days, 73% of colonic
G-MDSCs cells were detected as DiR positive, demonstrating
that these DiR+ G-MDSCs cells are WT MDSCs (Figure S5A).
Seventy-one percent of WT MDSCs were viable (Figure S5B).
As shown in Figures 6A–6C, transfer of G-MDSCs isolated
from WT mice treated with AOM/DSS to Cxcr2 null mice
restored the ability of AOM/DSS to induce tumor formation
and growth in Cxcr2-deficent mice. Histological analysis
revealed that only 2% of the tumors were adenocarcinomas
in Cxcr2-deficent mice injected with non-MDSC immune cells
or Cxcr2-deficient MDSCs. In contrast, 10% of the tumors
were adenocarcinomas in Cxcr2-deficent mice injected with
MDSCs, suggesting that MDSCs promotes tumor progression
(Figure 6D). An increased accumulation of MDSCs into colonic
mucosa in mice injected with MDSCs was observed as
compared to mice injected with non-MDSC immune cells and
Cxcr2-deficient MDSCs (Figure 6E). Moreover, immunofluores-
cence analysis confirmed an increased accumulation of
MDSCs into colonic mucosa and tumors in the MDSC re-
cipients (Figures S5C and S5D). These results demonstrate
that CXCR2-expressing MDSCs contribute to colitis-associated
tumor formation, growth, and progression.
MDSCs Suppress Cytotoxic Activity of Colonic CD8+ T
Cells
We further examined whether reduction of MDSCs in the colon
of Cxcr2/ mice resulted in induction of cytotoxic T cell
number and cytotoxicity against tumor cells in our AOM/DSS
model. As shown in Figure 7A, a great reduction in the number
of CD3+CD8+ T cells in tumors was observed when compared
to adjacent mucosa in both WT and Cxcr2/ mice. Although
the status of CXCR2 did not affect the number of cytotoxic
T cells in tumors, deletion of Cxcr2 led to an increase of cyto-
toxic T cell number in colonic mucosa but this change did not
achieve statistical significance. In contrast, colonic CD8+
T cells isolated from Cxcr2/ mice have higher cytotoxicity
against epithelial tumor cells isolated from AOM/DSS-treated
WT mice than colonic CD8+ T cells isolated from WT mice (Fig-
ure 7B). Importantly, CD8+ T cells isolated from tumors taken
from Cxcr2/ mice expressed high levels of CD107a, an acti-
vated CD8+ T cell marker, and produced more IFNg, Prf1, and
Gzmb when compared to tumor-associated CD8+ T cells from.
Figure 4. CXCR2 Ligands Are Elevated in Colitis-Associated Tumor and Matched Inflamed Mucosa
(A) CXCL1, CXCL2, and CXCL5 protein levels were measured in tumors (T) and adjacent mucosa (N) taken frommice treated with AOM/DSS as well as in normal
colon tissues taken from mice fed with water only as described in Figure 1A.
(B) CXCL1, CXCL2, and CXCL5 induced chemotaxis in WT MDSCs but not in Cxcr2/ MDSCs in vitro. WT and Cxcr2/ MDSCs were isolated from blood of
AOM/DSS-treated WT and Cxcr2/ mice, respectively.
Values are reported as the mean ± SEM (six mice for each group). *p < 0.05; **p < 0.01. See also Figure S3.
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T cells might kill tumor cells via induction of IFNg, Prf1, and
Gzmb. Moreover, colonic CD8+ T cell cytotoxicity against tu-
mor cells was suppressed by adding circulating G-MDSCs
taken from WT or Cxcr2/ mice (Figure 7C). The MDSC inhibi-
tion of CD8+ T cell cytotoxicity was ratio-dependent. Treatment
of AOM/DSS significantly induced arginase 1 expression and
activity as well as other suppressor markers such as CD80
and CD86 in both colonic WT and Cxcr2/ G-MDSCs (Figures
7D and 7E) and inhibited the secretion of interferon-gamma
(IFNg) and IL-2 from colonic CD8+ T cells in vitro (Figure 7F).
Although there were 27 downregulated genes in colonic
Cxcr2-deficient MDSCs as compared to WT MDSCs (Table
S1), none of these genes (except Cd80) are known to be
involved in MDSC immunosuppressive functions. These results
demonstrate that colonic MDSCs inhibit the ability of colonic
CD8+ T cells to kill tumor cells and their immunosuppressive
functions are CXCR2-independent. In addition, loss of CXCR2
increased the population of Th1 (CD4+IFNg+) cells and signifi-
cantly decreased the population of Th17 (CD4+IL-17A+) cells
in tumors, suggesting that CXCR2 signaling contributes to
the imbalance in Th1/Th2 responses and promotes tumor-
associated inflammation via enhancing Th17 cell number
(Figure S6C).CanDISCUSSION
The recognition that chronic inflammation caused by infections
or autoimmune diseases as an enabling characteristic of cancer
has highlighted the contribution of inflamed stroma to tumor initi-
ation, growth, progression, andmetastasis. Our findings not only
reveal howMDSCs are recruited to local inflamed tissues and the
tumor microenvironment and how local MDSCs contribute to
CRC progression, but also provide a rationale for developing
therapeutic approaches to subvert chronic inflammation- and
tumor-induced immunosuppression by using CXCR2 antago-
nists and neutralizing antibodies.
A growing body of evidence supports the important role of
chemokines and their receptors in colonic inflammation and
CRC (Wang et al., 2009). The levels of pro-inflammatory chemo-
kines are positively correlated with the inflammatory state in
patients with IBD (Wang et al., 2009). Genetic and pharmaco-
logic studies provide evidence showing that the activation of
pro-inflammatory CCL2, CCL3, or CCL4 signaling promotes
inflammation in mouse models where injurious agents are used
to induce experimental colitis (Andres et al., 2000; Khan et al.,
2006; Tokuyama et al., 2005). However, there are a few genetic
and pharmacologic studies showing the direct evidence that
CXC andCC chemokines contribute to colitis-associated cancercer Cell 24, 631–644, November 11, 2013 ª2013 Elsevier Inc. 637
Figure 5. PGE2 Treatment Increased Expression of CXCL1 and CXCL2 in Colonic Mucosa and Tumors
Eight-week-old male BALBc mice were treated with either 2 cycles of DSS alone (A) or AOM plus three cycles of DSS (B) with PGE2 or vehicle as described
in Experimental Procedures. The protein levels of CXCL1, CXCL2 and CXCL5 in colon (A) and colonic tumor (T) and matched mucosa (N) (B) were determined
by ELISA.
Data are represented as mean ± SEM (five mice for each group). *p < 0.05; **p < 0.01. See also Figure S4.
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evidence indicates that CCL2 promotes colitis-associated
tumorigenesis via recruitment of macrophages (Popivanova
et al., 2009). Moreover, deletion of an atypical chemokine recep-
tor D6, a decoy and scavenger receptor, increased susceptibility
to DSS-induced colitis and AOM/DSS-induced colitis-associ-
ated tumorigenesis accompanied with an increased production
of chemokines and inflammatory cell recruitment via lymphatic
endothelial cells (Vetrano et al., 2010). Our studies reveal that
CXCR2 promotes chronic colonic inflammation and colitis-asso-
ciated tumorigenesis via recruitment of G-MDSCs in the models
we tested. It has been well established that CXCR2 mediates
neutrophil migration and angiogenesis after ligand binding. In
humans, CXCR2 ligands include CXCL1, CXCL2, CXCL3,
CXCL5, CXCL6, CXCL7, and CXCL8. Among these ligands,
CXCL6 and CXCL8 also activate another receptor, CXCR1. In
mice, only CXCL1, CXCL2/3, CXCL5, and CXCL7 can bind to
CXCR2. These ligands and their receptor, CXCR2, have been
shown to play an important role not only in activation and recruit-
ment of neutrophils, but also in inducing exaggerated angiogen-
esis at sites of inflammation and tumors. For example, CXCR2
plays a key role in the recruitment of tumor-associated neutro-
phils, which promote tumor growth via enhancing angiogenesis
(Raccosta et al., 2013). The levels of CXCR2 ligands correlate638 Cancer Cell 24, 631–644, November 11, 2013 ª2013 Elsevier Incwith the inflammatory state in IBD patients and are elevated in
sporadic CRC in humans (Fegn and Wang, 2009), indicating
that the CXCR2 ligands and its receptor, CXCR2, may play a
role in IBD and CRC. However, the mechanisms underlying
the contribution of the CXCR2 signaling to CRC formation and
progression remain unclear. Our previous study showed that
CXCR2 is elevated mainly in endothelial and immune cells of
human colorectal carcinomas (Wang et al., 2006b), suggesting
that the CXCR2 signaling may promote tumorigenesis by
influencing the biological function of stromal compartments,
including immune cells, endothelial cells, or other cells. For
example, Moses’ group reported that inhibition of CXCR2
attenuated the fibroblasts-enhanced pancreatic ductal adeno-
carcinoma growth in a xenograft model (Ijichi et al., 2011), sug-
gesting that fibroblast CXCR2 contributes to tumor growth.
However, we did not observe CXCR2 expression on colonic
tumor-associated fibroblasts. Recently, Jamieson et al. re-
ported that CXCR2 is required for colonic chronic inflammation
and colitis-associated tumorigenesis, which is consistent with
our results (Jamieson et al., 2012). We extended the scope of
our research to reveal that CXCR2 is required for homing of
MDSCs from the circulatory system to the colonic mucosa in
both normal and chronic inflammatory conditions as well as
colitis-associated tumors..
Figure 6. Transfer of WT MDSCs to Cxcr2-Deficent Mice Restores AOM/DSS-Induced Colitis-Associated Tumorigenesis
WT G-MDSCs, Ly6G- immune cells (non-MDSC), or Cxcr2/ G-MDSCs were intravenously (i.v.) injected into Cxcr2/ mice as described in the Experimental
Procedures. The mice were treated with AOM/DSS as described in the Experimental Procedures.
(A) Gross view of colonic tumor of AOM/DSS-treated WT and Cxcr2/ mice with non-MDSC immune cells, G-MDSCs, or Cxcr2-deficient G-MDSCs (scale
bar, 0.5 cm).
(B) Tumor number was counted based on the size. The data were represented as mean ± SEM of average of the tumor number in each size group and all groups.
(C) Representative of H&E-stained sections of tumors from each group (scale bar, 100 mm).
(D) Blinded histological scoring of average percentage of adenocarcinomas fromWT and Cxcr2/mice with non-MDSC immune cells, WT MDSCs or Cxcr2/
MDSCs.
(E) The numbers of colonic MDSCs in WT mice or Cxcr2/ mice treated with AOM and two cycles of DSS after transfer injection of indicated cells. Data are
represented as mean ± SEM. *p < 0.05; **p < 0.01. See also Figure S5.
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Figure 7. Loss of CXCR2 Does Not Affect CD3+CD8+ T Cell Number but Enhances CD8+ T Cell Cytotoxicity against Tumor Cells
(A) CD3+CD8+ cell number in tumors (T) and adjacent mucosa (N) taken from WT and Cxcr2/ mice were determined by flow cytometry.
(B) Cytotoxicity of colonic CD8+ T cells (E) isolated from WT and Cxcr2/ mice against tumor cells (T) isolated from tumors of AOM/DSS-treated WT mice was
determined as described in the Experimental Procedures.
(C) CD8+ T cells isolated from WT and Cxcr2/mice, tumor cells isolated from tumors of AOM/DSS-treated WT mice, and MDSCs isolated from blood of either
WT or Cxcr2/ mice were cultured. The ratio of CD8+ T cells and tumor cells is 50:1.
(D) The levels of arginase 1 expression (left) and arginase activity (right) in colonic MDSCs isolated from indicated mice treated with water or AOM/DSS (A/D).
(E) The percentage of CD80+ or CD86+ MDSCs in colonic MDSCs from indicated mice.
(F) Levels of IFNg and IL-2 secreted fromWTCD8+ T cells coculturedwith tumor cells (E:T = 50:1) in the presence of different ratios ofMDSCs from indicatedmice.
Data are represented as mean ± SEM (six mice for each group). *p < 0.05; **p < 0.01. See also Figure S6 and Table S1.
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and cancer patients, but also in autoimmunity and during inflam-
mation, including IBD (Haile et al., 2008). However, themolecular
mechanism(s) underlying recruitment of MDSCs into the tumor640 Cancer Cell 24, 631–644, November 11, 2013 ª2013 Elsevier Incmicroenvironment and inflammatory sites remain unclear. In
tumor implantation models, CXCL1/2 has recently been shown
to mediate mammary tumor growth and lung metastasis and
CXCL1/2 knockdown in a breast cancer cell line is associated.
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inhibition of CXCR2 by its antagonist does not suppress mouse
mammary adenocarcinoma growth, despite partially reducing
CD11b+Gr1+ cell abundance in tumor implantation models
(Yang et al., 2008). Moreover, a recent report showed that
CXCL8 (IL-8)-overexpressing transgenic mice exhibited more
infiltration of immature myeloid cells into colonic mucosa
following DSS treatment (Asfaha et al., 2013). Because CXCL8
binds to both CXCR1 and CXCR2 receptors, it is not clear which
receptor mediates the effect of CXCL8 on promoting the recruit-
ment of immature myeloid cells. Although these studies have
brought up the possibility that CXCR2 ligands are involved in
recruitment of myeloid cells, the role of CXCR2 in MDSCs
has remained ambiguous. It has been well established that
inflammatory mediators such as cytokines induce pro-
inflammatory or angiogenic chemokines. Since the inflammatory
COX-2-PGE2 pathway plays a key role in inflammation and
cancer, our results indicate that this bioactive lipid may promote
homing of MDSCs into colon via the CXCR2 ligand-CXCR2
signaling. Further studies are required to test this hypothesis.
Collectively, these results explain how CXCR2-expressing
MDSCs migrate to inflamed colonic mucosa and colitis-associ-
ated tumors.
Although evidence for MDSC promotion of immunosuppres-
sion is accumulating, it is still unknown whether MDSCs play a
key role in colitis-associated carcinogenesis. Our results from
the transfer experiments provide direct evidence demonstrating
that MDSCs contribute to colitis-associated tumorigenesis. In
addition to CXCR20s role in leukocyte recruitment and as a
pro-angiogenic factor for angiogenesis, CXCR2 signaling also
promotes cellular proliferation, survival, and migration of mela-
noma, prostate cancer, and esophageal cancer cells (Luan
et al., 1997; Maxwell et al., 2007;Wang et al., 2006a). It is of great
interest to determine the biological functions of CXCR2 in human
CRC cells.
It is widely accepted that MDSCs have suppressive effects on
both the innate immune response via NK cells and the adaptive
immune response via T cells by direct cell-cell contact. In our
mouse model of colitis-associated carcinogenesis, MDSCs do
promote tumor growth via inhibition of CD8+ T cell function.
There are several proposed mechanisms to explain howMDSCs
suppress T cells (Gabrilovich and Nagaraj, 2009). One proposed
mechanism indicates that MDSCs inhibit T cell proliferation by
reducing L-arginine (Gabrilovich and Nagaraj, 2009). However,
we did not observe a significant impact of Cxcr2 deletion on
CD8+ T cell populations in both colonic inflamed mucosa and
colitis-associated tumors in our mouse model. In contrast, we
did find that local colonic MDSCs inhibited cytotoxic activity of
colonic CD8+ T cells against tumor cells. Since arginase 1 is
required for immunosuppressive effects of MDSCs on CD8+
T cell cytotoxicity (Grivennikov et al., 2009), our results show
that colonic MDSCs express arginase 1 that is active and inhibit
the secretion of IFNg and IL-2 from colonic CD8+ T cells,
suggesting that MDSCs inhibit tumor formation, growth, and
progression via induction of arginase 1, CD80, and CD86.
Further studies are needed to test our hypothesis. Interestingly,
CXCR2 was not required for the immunosuppressive function of
MDSCs in inhibiting CD8+ T cell cytotoxic activity against tumor
cells in our model. In addition, it is possible that NK cells may beCaninvolved in the contribution of MDSCs to tumor growth.
Moreover, emerging evidence revealed that MDSCs inhibited
the binding of a specific tumor-associated peptide to tumor
cell-associated MHC, resulting in a resistance of tumor cells to
antigen-specific cytotoxic T cells (Lu et al., 2011). Further
research is required to determine the exact mechanism(s) by
which MDSCs allow tumor cells to escape from immunosurveil-
lance. Previous studies showed that IL-6 secreted from MDSCs
is essential for attenuating differentiation of tumor-specific CD4+
T cells into Th1 cells (Tsukamoto et al., 2013) and expression of
TNFR-2 (Fas family member) in MDSCs is necessary for their
survival (Zhao et al., 2012). Our observation that loss of CXCR2
resulted in reduction of Il-6 and Fas mRNA levels in MDSCs
may explain why loss of CXCR2 increased the population of
Th1 and why Cxcr2-deficient MDSCs had a shorter half-life.
Collectively, these results indicate that CXCR2 is essential for
G-MDSC infiltration into colonic mucosa and tumors, which
promotes tumor growth and progression via inhibition of CD8+
T cell cytotoxic activity.
Th17 cells have been found to play a key role in IBD and may
change our thinking of the Th1 and Th2 dichotomy as playing
the major role in IBD (Harrington et al., 2006; Steinman, 2007).
For example, in vivo studies indicated that Th17 cells promote
inflammation via induction of multiple inflammatory pathways
(Monteleone et al., 2012). The elevation of genes (IL17A and
RORC) associated with Th17 cells is correlated with a poor prog-
nosis in human CRC patients (Tosolini et al., 2011). Interestingly,
MDSCs have been shown to enhance the differentiation of naive
CD4+ T cells into Th17 cells under Th17-polarizing conditions
in vitro (Yi et al., 2012). Our in vivo results show that MDSCs posi-
tively correlated with Th17 cells in tumors of AOM/DSS-treated
mice. Future studies are needed to investigate whether MDSCs
promotes Th17 cell differentiation in vivo.
In summary, CXCR2 is required for G-MDSC trafficking into
colonic inflamed mucosa and the tumor microenvironment and
is critical for colitis-associated tumor formation, growth, and
progression. An inflammatory mediator, PGE2, induces CXCR2
ligand expression in colonic mucosa and tumors. These findings
provide comprehensive insights into how MDSCs are recruited
to local inflamed tissues and to the tumor microenvironment
and how local MDSCs contribute to CRC progression.
Moreover, our work sheds light on how the inflammatory micro-
environment contributes to cancer immune evasion by allowing
tumor cells to escape from immunosurveillance. Our results pro-
vide a rationale to develop CXCR2 antagonists and neutralizing
antibodies as therapeutic approaches subverting tumor-induced
immunosuppression.EXPERIMENTAL PROCEDURES
Reagents
All reagents are provided in the Supplemental Experimental Procedures.
Animal Models
All animal experiments conform to our animal protocols that were reviewed
and approved by the Institutional Animal Care and Use Committee of the
MD Anderson Cancer Center and the Arizona State University. Cxcr2/ in
BALBc genetic background and their littermate control (WT)mice andApcMin/+
mice were obtained from the Jackson Laboratory. Information for the animal
experiments is presented in the Supplemental Experimental Procedures.cer Cell 24, 631–644, November 11, 2013 ª2013 Elsevier Inc. 641
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Colonic immunocytes were isolated according to the previous report (Vezys
et al., 2000). Details of isolation of colonic immune cells as well as immu-
nocytes in other organs are provided in the Supplemental Experimental Proce-
dures. Flow cytometry analysis was performed on 1 3 106 of immunocytes
isolated from colon, blood, bone marrow, spleen, liver, and lung.
Flow Cytometry Analysis
For multicolor flow cytometry analysis, cells were stained with indicated
monoclonal antibodies and analyzed on a Gallios flow cytometer (Beckman
Coulter) as previously described (Zeng et al., 2012). The flow cytometric pro-
files were analyzed by counting 20,000 events using Kaluza software program
(Beckman Coulter). DAPI or PI was used to exclude the dead cells during anal-
ysis of immune cell profiles. Information on antibodies and description of the
experimental procedures are presented in the Supplemental Experimental
Procedures.
Quantitative PCR and Mouse TaqMan Immune Panel
RNA was extracted from colonic MDSCs or homogenized intestinal tumor and
normal mucosa using an RNeasy Mini Kit (QIAGEN) and reverse-transcribed
with iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad). TaqMan
real-time qPCR and qPCR TaqMan mouse immune arrays were performed on
a ViiA7 (Applied Biosystems). Additional information on primers, TaqMan Array
Mouse Immune Cards, and description of the experimental procedures are
provided in the Supplemental Experimental Procedures.
ELISA
Information on extraction of total proteins from colon tissues and ELISA kits
are provided in the Supplemental Experimental Procedures.
Chemotaxis Assay
The procedure describing the chemotaxis assay is presented in the
Supplemental Experimental Procedures.
Immunohistochemistry and Immunofluorescence Staining
Immunohistochemistry and immunofluorescence staining were performed
according to previous reports (Katoh et al., 2010, 2012). Detailed information
on antibodies and description of the experimental procedures are provided
in the Supplemental Experimental Procedures.
CTL Assay
CD8+ T cells were isolated from colonic mucosa of AOM/DSS-treated mice as
effector cells (E) by CD8+ T Cell Isolation Kit II (Miltenyi) according to the
manufacturer’s instructions. MDSCs were isolated from blood of AOM/DSS-
treated WT mice as mentioned above. Isolation and culture of target tumor
cells (T) as well as the procedures of CTL assay are described in the
Supplemental Experimental Procedures.
Statistical Analysis
Each in vitro experiment was done at least three times and each in vivo
experiment was conducted at least twice. Data are presented as mean ±
SEM. Comparisons among multiple groups were performed by factorial
analysis of variance, followed by Bonferroni test. Comparisons between two
groups were performed with Student’s t test or Mann-Whitney U test where
appropriate. Fischer’s exact test was used for categorical variables. A
p value < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2013.10.009.
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